Compare Kinross Gold Corporation (KGC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Kinross Gold Corporation is far larger — about 12.9× Recursion Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KGC | RXRX | |
|---|---|---|
Market Cap | $27.62B | $2.14B |
Volume | 6,347,266 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $6.79 |
52-Week Low | $22.47 | $2.84 |
Typical Hold Time | 53 Days | 23 Days |
Enterprise Value | $25.70B | $1.66B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KGC trades at $23.34, up 0.69% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong fundamentals, with Q2 2026 EPS beating estimates at $0.71 and robust cash flow growth, though recent news highlights production guidance cuts and legal investigations. Valuation ratios remain attractive, with a P/E of 8.87 and EV/EBITDA of 4.59.
The outlook is mixed: strong earnings and cash flow support upside to the $38.80 consensus price target, but risks include cost pressures, production setbacks, and legal scrutiny. Analyst sentiment is bullish with 59% buy ratings, but investors should weigh operational execution against macroeconomic gold price volatility.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
